Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
non-nucleoside reverse transcriptase inhibitor |
| gptkbp:approvalYear |
1997
|
| gptkbp:ATCCode |
gptkb:J05AG03
|
| gptkbp:brand |
gptkb:Rescriptor
|
| gptkbp:CASNumber |
gptkb:136817-59-9
|
| gptkbp:developedBy |
gptkb:Pharmacia_&_Upjohn
|
| gptkbp:eliminationHalfLife |
5.8 hours
|
| gptkbp:hasMolecularFormula |
C22H28N6O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
delavirdine
|
| gptkbp:KEGGID |
D02341
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 reverse transcriptase
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1227
gptkb:DB00705 1486 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache rash |
| gptkbp:status |
FDA approved
|
| gptkbp:synonym |
U-90152T
|
| gptkbp:UNII |
8I6V6Q122V
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:withdrawn |
gptkb:Canada
gptkb:European_Union |
| gptkbp:bfsParent |
gptkb:NNRTIs
|
| gptkbp:bfsLayer |
5
|